Lu Peng-Jun, Hung Mei-Chuan, Srivastav Anup, Williams Walter W, Dooling Kathleen L
Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Leidos Inc., Atlanta, Georgia.
Am J Prev Med. 2020 Jul;59(1):21-31. doi: 10.1016/j.amepre.2020.01.017. Epub 2020 May 7.
In 2006, zoster vaccine live was recommended for adults aged ≥60 years. In 2011, zoster vaccine live was approved for use but not recommended for adults aged 50-59 years. This study assessed zoster vaccine live coverage among adults aged 50-59 years and ≥60 years.
Data from the 2013-2017 National Health Interview Surveys were analyzed in 2019 to estimate national zoster vaccine live coverage among adults aged ≥50 years. State-specific zoster vaccine live coverage among adults aged ≥50 years was assessed using 2017 Behavioral Risk Factor Surveillance System data.
Among adults aged 50-59 years, zoster vaccine live coverage was 5.7% in 2017, ranging from 4% to 6% during 2013-2017 (test for trend, p>0.05). Zoster vaccine live coverage among adults aged 50-59 years ranged from 5.8% in Pennsylvania to 14.7% in South Dakota. By 2017, zoster vaccine live was received by 34.9% of adults aged ≥60 years, a significant increase from 24.2% in 2013. Zoster vaccine live coverage among adults aged ≥60 years in 2017 ranged from 26.0% in Mississippi to 51.8% in Vermont. In 2017, major characteristics significantly associated with increased likelihood of zoster vaccine live vaccination among adults aged 50-59 years and ≥60 years were older age, having 4 to 9 physician contacts in the past 12 months, and having a usual place for health care.
This study provides an assessment of zoster vaccine live coverage among adults aged ≥50 years before the newly recommended recombinant zoster vaccine came into widespread use. Providers should routinely assess adults' vaccination status and strongly recommend or offer needed vaccines to their patients.
2006年，推荐60岁及以上成年人接种重组带状疱疹疫苗。2011年，重组带状疱疹疫苗获批使用，但不推荐50 - 59岁成年人接种。本研究评估了50 - 59岁及60岁及以上成年人中重组带状疱疹疫苗的接种率。
2019年对2013 - 2017年国家健康访谈调查数据进行分析，以估算50岁及以上成年人中重组带状疱疹疫苗的全国接种率。使用2017年行为危险因素监测系统数据评估50岁及以上成年人中各州的重组带状疱疹疫苗接种率。
在50 - 59岁成年人中，2017年重组带状疱疹疫苗接种率为5.7%，2013 - 2017年期间为4%至6%（趋势检验，p>0.05）。50 - 59岁成年人中重组带状疱疹疫苗接种率在宾夕法尼亚州为5.8%，在南达科他州为14.7%。到2017年，60岁及以上成年人中有34.9%接种了重组带状疱疹疫苗，较2013年的24.2%有显著增加。2017年，60岁及以上成年人中重组带状疱疹疫苗接种率在密西西比州为26.0%至佛蒙特州为51.8%。2个年龄组中，2017年与重组带状疱疹疫苗接种可能性增加显著相关的主要特征为年龄较大、在过去12个月内有4至9次医生问诊以及有固定的医疗保健场所。
本研究在新推荐的重组带状疱疹疫苗广泛使用之前，对50岁及以上成年人中重组带状疱疹疫苗接种率进行了评估。医疗服务提供者应定期评估成年人的疫苗接种状况，并强烈推荐或为患者提供所需疫苗。
